OCT 03, 2018 7:15 AM PDT

Natural Killers for HIV Vaccine

WRITTEN BY: Nicholas Breehl

Human immunodeficiency virus or HIV is still a disease with no cure. With the incidence rate in the United States, reported by the Centers for Disease Control and Prevention (CDC), at 38,500 diagnoses in 2015, scientists across the globe continue to work diligently to combat HIV.

A team of researchers from Duke Human Vaccine Institute has recently published their work regarding the interplay of natural killer cells (NK cells) and broadly neutralizing antibodies (bnAbs) in the journal Cell. Their efforts hope to provide insight into the development of a vaccine that can be made to protect individuals from future infection.

About half of those infected with HIV experience production of broadly neutralizing antibodies, while the other 50% do not develop bnAbs. Broadly neutralizing antibodies are naturally occurring antibodies that develop too late in ones HIV infection to provide any benefit. This is because HIV has a high mutation rate and the antibodies would no longer recognize the virus.

If administered early enough, the bnAbs show potential in the development and efficacy of a vaccine. To begin, the researchers must understand the molecular mechanisms of host control of bnAb induction. To this end, the team performed a transcriptome analysis of the blood from about 50 HIV-1 bnAb producing patients and around 50 patients with HIV-1 that do not produce bnAbs. Transcriptome analysis is a catalog of the complete set of RNA transcripts that are generated by the genome.

The scientists observed an upregulation of RAB11FIP5 gene that encodes a Rab protein associated with endosomes. NK cells had the highest expression of the gene, which is presumed to be related to dysfunction of the NK cells. NK cells are involved in the regulation of immune cells, specifically CD4+ T follicular helper cells, the cells that interact with B cells to produce antibodies.

This data suggest that NK cells and Rab11 are part of the regulation of HIV-1 bnAb development.

Barton Haynes, M.D., director of the Duke Human Vaccine Institute and senior author of the study says, “This type of immune cell wasn’t previously known to regulate bnAbs. We found a new natural killer cell pathway that appears to be important in regulating the bnAb production.”

Todd Bradley, Ph. D., a lead author of the study, states, “This is a new pathway that we hope to modulate during vaccination to generate a better HIV antibody response.”

The research team identifies future work should focus to identify the specific receptor-ligand interactions involved in triggering of NK cell lysis of CD4+ T cells. They would also like to see if blocking these interactions improves antibody responses during vaccination.

Sources: Science Direct, Science Daily, CDC, Youreka Science

About the Author
Masters
You May Also Like
MAR 22, 2022
Microbiology
When Different Microbes are Present, Antibiotics are Less Effective
MAR 22, 2022
When Different Microbes are Present, Antibiotics are Less Effective
Although antibiotic resistance is becoming a problem, many bacterial infections can still be prevented or eliminated wit ...
MAR 22, 2022
Health & Medicine
Back to Nature: the Health Benefits of Nature Prescriptions
MAR 22, 2022
Back to Nature: the Health Benefits of Nature Prescriptions
With modern amenities and luxuries, it's easy to be unaware of just how much we may neglect the outdoors and its hea ...
MAR 30, 2022
Drug Discovery & Development
Universal Flu Vaccine Shows Promise in Mice
MAR 30, 2022
Universal Flu Vaccine Shows Promise in Mice
Just one dose of a new vaccine candidate may protect against multiple strains of flu. The corresponding research was pub ...
APR 01, 2022
Drug Discovery & Development
Pill Form of Remdesivir Treats COVID-19 in Mice
APR 01, 2022
Pill Form of Remdesivir Treats COVID-19 in Mice
A pill form of remdesivir, an antiviral drug currently administered intravenously, may be able to treat COVID-19 in mice ...
MAY 10, 2022
Immunology
A Failed Immunotherapy Trial Leads to a Crucial Discovery
MAY 10, 2022
A Failed Immunotherapy Trial Leads to a Crucial Discovery
Immunotherapies, which boost a patient's immune system so it's better at fighting cancer, have been a game-chang ...
MAY 20, 2022
Health & Medicine
Second COVID Boosters Not Recommended for All Adults
MAY 20, 2022
Second COVID Boosters Not Recommended for All Adults
In previous studies in Israel, vaccine-induced COVID immunity was reported to decrease as early as three  ...
Loading Comments...